Connect with us

Hi, what are you looking for?

Wednesday, Mar 22, 2023
Mugglehead Magazine
Alternative investment news based in Vancouver, B.C.


Tilray receives approval for CBD oral solution in Australia and New Zealand

Flagship product from company’s medical cannabis division now set for clinical trial use

Tilray acquires approval for CBD100 from Natural Health Science Foundation
Photo via Tilray Medical

Tilray Brands, Inc. (Nasdaq: TLRY; TSX: TLRY) has now received some desired approval for its flagship oral solution (OS) from a renowned non-profit organization and government department.

On Tuesday, the company’s medical cannabis division, Tilray Medical, received validation and approval from the Natural Health Science Foundation (NHSF) for its Purified OS CBD100 product which will be utilized in clinical trials conducted in New Zealand and Australia.

Additionally, the New Zealand Ministry of Health has also given its validation for Tilray’s OS product after meeting the required quality standards.

Read more: Poland approves Tilray Medical products for distribution and wholesale

Read more: Jointly releases data showcasing cannabis health benefits

Tilray ANZ is a division of Tilray Brands dedicated to medical cannabis and the NHSF is a non-profit organization focused on assessing the quality of natural health products. The New Zealand Ministry of Health is a department of the NZ government responsible for healthcare in the country.

“We are extremely pleased with this outcome and proud to provide EU-GMP certified products to patients in Australia and New Zealand. Having our product quality validated by the NHSF demonstrates Tilray’s commitment to delivering the highest quality cannabis products to our patients,” said George Polimenakos, General Manager at Tilray ANZ (Australia, New Zealand).

“Tilray Purified OS CBD100 has been thoroughly assessed by independent experts and has met the Quality & Equivalence standards of the Natural Health Science Foundation. This means the product has a basis of reproducibility which serves as a valid medical intervention, from a scientific point of view, for patient use and to test in a clinical trial,” added Nigel Pollard, Chairman at the NHSF.

Tilray stock increased by 0.11 per cent on Tuesday to $4.60 on the Toronto Securities Exchange.

Photo via Tilray ANZ


Follow Mugglehead on Twitter

Like Mugglehead on Facebook


Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

You May Also Like

Stock News

The company is planning an internal reorganization to meet the eligibility criteria and minimum requirements for listing


An independent study in B.C. found concerning numbers and pot sold in other provinces was also found to be mislabelled


Adastra's stock rose by about 48% Friday on the Canadian Securities Exchange then dropped over the weekend


The company will supply Mind Medicine Australia with the substances, now considered designated therapies in the country